Allogene Therapeutics ALLO

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

No daily data currently available, please try a different date range.

About

Allogene Therapeutics (ALLO) Business Model and Operations Summary
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Key Insights

Allogene Therapeutics (ALLO) Core Market Data and Business Metrics
  • Latest Closing Price

    $1.45
  • Market Cap

    $315.03 Million
  • Total Outstanding Shares

    217.27 Million Shares
  • Total Employees

    361
  • Dividend

    No dividend
  • IPO Date

    October 11, 2018
  • SIC Description

    Biological Products, (no Disgnostic Substances)
  • Primary Exchange

    NASDAQ
  • Headquarters

    210 East Grand Avenue, South San Francisco, CA, 94080

Historical Stock Splits

Execution DateSplit Amount

Short Volume

Daily short volume activity identifies short-term trading pressure and potential price volatility

Short Interest

Short Interest

This information represents bi-monthly aggregated short interest data reported to the Financial Industry Regulatory Authority (FINRA) by broker-dealers.

Settlement Date: The date on which the short interest data is considered settled, typically based on exchange reporting schedules.

Short Interest: The total number of shares that have been sold short but have not yet been covered or closed out.

Avg Daily Volume: The average daily trading volume for the stock over the specified period, typically used to contextualize short interest.

Days To Cover: The estimated number of days it would take to cover all short positions based on average trading volume.

Bi-monthly short interest levels can be used to gauge bearish market sentiment and short squeeze potential

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about ALLO from trusted financial sources